288 related articles for article (PubMed ID: 33213245)
21. Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.
Li X; Huang H; Xu B; Guo H; Lin Y; Ye S; Yi J; Li W; Wu X; Wang W; Zhan H; Xie D; Peng J; Cao Y; Pu X; Guo C; Hong H; Wang Z; Fang X; Zhou Y; Lin S; Liu Q; Lin T
Cancer Res Treat; 2019 Jul; 51(3):919-932. PubMed ID: 30282447
[TBL] [Abstract][Full Text] [Related]
22. Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Choi YW; Jeong SH; Ahn MS; Lee HW; Kang SY; Choi JH; Jin UR; Park JS
J Korean Med Sci; 2014 Nov; 29(11):1493-500. PubMed ID: 25408580
[TBL] [Abstract][Full Text] [Related]
23. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation.
Knight C; Hind D; Brewer N; Abbott V
Health Technol Assess; 2004 Sep; 8(37):iii, ix-xi, 1-82. PubMed ID: 15361313
[TBL] [Abstract][Full Text] [Related]
24. How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma.
Falduto A; Cimino F; Speciale A; Musolino C; Gangemi S; Saija A; Allegra A
Blood Rev; 2017 Jul; 31(4):235-249. PubMed ID: 28262268
[TBL] [Abstract][Full Text] [Related]
25. Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis.
Lee L; Crump M; Khor S; Hoch JS; Luo J; Bremner K; Krahn M; Hodgson DC
Br J Haematol; 2012 Aug; 158(4):481-8. PubMed ID: 22671571
[TBL] [Abstract][Full Text] [Related]
26. [Comparison between efficacy and safety of rituximab plus CHOP regimen and CHOP regimen for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Xu W; Li JY; Zhang ZH; Qiu HX; Qian SX; Wu HX; Lu H; Sheng RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):933-7. PubMed ID: 18718094
[TBL] [Abstract][Full Text] [Related]
27. [A comparative study of induction chemotherapy with or without autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed young medium/high risk diffuse large B cell lymphoma patients].
Wang X; Xia B; Wang CY; Li MZ; Xu W; Yuan T; Tian C; Zhao HF; Yang HL; Zhao ZG; Wang XF; Wang YF; Yu Y; Zhang YZ
Zhonghua Xue Ye Xue Za Zhi; 2019 Feb; 40(2):117-124. PubMed ID: 30831626
[No Abstract] [Full Text] [Related]
28. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
[TBL] [Abstract][Full Text] [Related]
29. Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.
Herbrecht R; Cernohous P; Engert A; Le Gouill S; Macdonald D; Machida C; Myint H; Saleh A; Singer J; Wilhelm M; van der Jagt R
Ann Oncol; 2013 Oct; 24(10):2618-2623. PubMed ID: 23946328
[TBL] [Abstract][Full Text] [Related]
30. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T; Jin J; Pylypenko H; Verhoef G; Siritanaratkul N; Drach J; Raderer M; Mayer J; Pereira J; Tumyan G; Okamoto R; Nakahara S; Hu P; Appiani C; Nemat S; Cavalli F;
Lancet Oncol; 2018 Nov; 19(11):1449-1458. PubMed ID: 30348538
[TBL] [Abstract][Full Text] [Related]
31. Treatment of gastrointestinal diffuse large B cell lymphoma in China: a 10-year retrospective study of 114 cases.
Li X; Shen W; Cao J; Wang J; Chen F; Wang C; Zou S; Shen B; Zhao R; Li J; Shen Z
Ann Hematol; 2012 Nov; 91(11):1721-9. PubMed ID: 22733613
[TBL] [Abstract][Full Text] [Related]
32. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
[TBL] [Abstract][Full Text] [Related]
33. R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: A randomized, open-label, noninferiority phase 3 trial.
Hara T; Yoshikawa T; Goto H; Sawada M; Yamada T; Fukuno K; Kasahara S; Shibata Y; Matsumoto T; Mabuchi R; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Nannya Y; Katsumura N; Takahashi T; Kito Y; Takami T; Miyazaki T; Takeuchi T; Shimizu M; Tsurumi H
Hematol Oncol; 2018 Oct; 36(4):638-644. PubMed ID: 29882279
[TBL] [Abstract][Full Text] [Related]
34. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
35. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
[TBL] [Abstract][Full Text] [Related]
36. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Poeschel V; Held G; Ziepert M; Witzens-Harig M; Holte H; Thurner L; Borchmann P; Viardot A; Soekler M; Keller U; Schmidt C; Truemper L; Mahlberg R; Marks R; Hoeffkes HG; Metzner B; Dierlamm J; Frickhofen N; Haenel M; Neubauer A; Kneba M; Merli F; Tucci A; de Nully Brown P; Federico M; Lengfelder E; di Rocco A; Trappe R; Rosenwald A; Berdel C; Maisenhoelder M; Shpilberg O; Amam J; Christofyllakis K; Hartmann F; Murawski N; Stilgenbauer S; Nickelsen M; Wulf G; Glass B; Schmitz N; Altmann B; Loeffler M; Pfreundschuh M; ;
Lancet; 2019 Dec; 394(10216):2271-2281. PubMed ID: 31868632
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B-cell lymphoma.
Kayamori K; Shono K; Onoda M; Yokota A
Hematology; 2019 Dec; 24(1):52-59. PubMed ID: 30101679
[TBL] [Abstract][Full Text] [Related]
38. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma.
Wöhrer S; Püspök A; Drach J; Hejna M; Chott A; Raderer M
Ann Oncol; 2004 Jul; 15(7):1086-90. PubMed ID: 15205203
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
40. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group.
Pfreundschuh M; Poeschel V; Zeynalova S; Hänel M; Held G; Schmitz N; Viardot A; Dreyling MH; Hallek M; Mueller C; Wiesen MH; Witzens-Harig M; Truemper L; Keller U; Rixecker T; Zwick C; Murawski N
J Clin Oncol; 2014 Dec; 32(36):4127-33. PubMed ID: 25403207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]